The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ib study of investigational pan-RAF kinase inhibitor MLN2480 plus investigational TORC1/2 inhibitor MLN0128, investigational Aurora A kinase inhibitor alisertib (MLN8237), or paclitaxel in patients (pts) with advanced solid tumors.
 
Anthony J. Olszanski
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech; Merck; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst)
 
Mark R. Middleton
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Roche Pharma AG
Research Funding - Amgen; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Eisai; GlaxoSmithKline; Immunocore; MedImmune; Merck; Pfizer; Roche Pharma AG; Vertex
 
Rastilav Bahleda
No Relationships to Disclose
 
Rebecca Suk Heist
Consulting or Advisory Role - Boehringer Ingelheim; Momenta Pharmaceuticals
Research Funding - Celgene; Debiopharm Group; EMD Serono; Exelixis; Genentech/Roche; GlaxoSmithKline; Mirati Therapeutics; Peregrine Pharmaceuticals; Sanofi
 
Lakshmi Rangachari
Employment - Millennium
 
Xiaofei Zhou
Employment - Millennium
 
Viviana Bozón
Employment - Millennium
Stock and Other Ownership Interests - Millennium
Travel, Accommodations, Expenses - Millennium
 
Michelle Kneissl
Employment - Millennium
Stock and Other Ownership Interests - Millennium
 
Teresa Macarulla
No Relationships to Disclose